What is NovoCure's other long-term liabilities?

NovoCure (NVCR) reported other long-term liabilities of -$2.84M in Q1 2026.

How has NovoCure's other long-term liabilities changed year-over-year?

NovoCure's other long-term liabilities decreased by 153.1% year-over-year, from -$1.12M to -$2.84M.

What is the long-term trend for NovoCure's other long-term liabilities?

Over 4 years (2021 to 2025), NovoCure's other long-term liabilities has grown at a -16.7% compound annual growth rate (CAGR), from -$10.98M to -$5.27M.

NovoCure NVCR Other long-term liabilities

Other long-term liabilities at other companies

Hilton WorldwideHLT

-$14M+3.4%

MSCIMSCI

$4.9M+644%

American TowerAMT

$12.55M+129%

Bloom EnergyBE

-$86K-126%

Meta Platforms, Inc.META

-$5.17B-827%

AmetekAME

$18.19M+276%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's other long-term liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's other long-term liabilities?: NovoCure (NVCR) reported other long-term liabilities of -$2.84M in Q1 2026.
How has NovoCure's other long-term liabilities changed year-over-year?: NovoCure's other long-term liabilities decreased by 153.1% year-over-year, from -$1.12M to -$2.84M.
What is the long-term trend for NovoCure's other long-term liabilities?: Over 4 years (2021 to 2025), NovoCure's other long-term liabilities has grown at a -16.7% compound annual growth rate (CAGR), from -$10.98M to -$5.27M.